No Effect of Hepatic Impairment on the Pharmacokinetics of Serelaxin, a Recombinant Human Relaxin-2 in Development for the Treatment of Acute Heart Failure

Authors
Kobalava Z. 1 , Halabi A.2 , Zahringer A.3 , Pang Y.4 , Dahlke M.5
Journal
Circulation
Publisher
Lippincott Williams & Wilkins
Number of issue
22
Language
English
Status
Published
Volume
128
Year
2013
Organizations
  • 1 Peoples Friendship Univ Russia, Dept Internal Dis Cardiol & Clin Pharmacol, Moscow, Russia
  • 2 Kiel GmbH, Clin Rsch Serv, CRS, Kiel, Germany
  • 3 Novartis Pharma AG, NIBR, Basel, Switzerland
  • 4 Novartis Inst BioMed Rsch, Cambridge, MA USA
  • 5 Novartis Pharma AG, Translat Med, Basel, Switzerland
Keywords
Acute heart failure; Pharmacokinetics; Drugs
Cite
ГОСТ MLA RIS BibTex
Share

Other records